The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage. If approved, the ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...

If approved by the EMA, mavorixafor would be the first drug indicated for patients with WHIM syndrome in Europe, a population estimated to be approximately 1,000 people. Earlier this month X4 ...

We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...

Psychedelic therapy is set to launch in Colorado this spring, with the state considering licenses for healing centers, ...

Planters NUTmobile drivers plan and execute more than 200 events across the country for one full-time paid year.

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

The savings on the 25 drugs stem from a new law that allows Medicare to haggle over the price it pays on the most popular and expensive prescription drug scripts filled by older Americans.